----
Current ValuationThe current P/E ratio is 32.50, below the reasonable range, cheaper than 85.38% of the time in the past 1 years, and the industry ranks 17/74, the industry Median --.
32.5xP/E
$60.11Stock price
$1.85Earnings per share
32.5xP/E
Stock price$60.11Earnings per share$1.85
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- 43.00x
- Typical range
- 33.52x–53.38x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
09182736
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x40x80x120x160x200x
| Name/Symbol | |||
|---|---|---|---|
CVSUSCVS Health | 24.45x | 394.45% | $119.55B |
DGXUSQuest Diagnostics | 23.73x | 17.81% | $26.70B |
LHUSLabcorp | 26.62x | 36.46% | $26.68B |
BTSGUSBrightSpring Health Services | 32.50x | 86.70% | $11.89B |
CHEUSChemed | 27.26x | 26.94% | $7.50B |
OPCHUSOption Care Health | 22.31x | 18.20% | $4.68B |
CRVLUSCorVel | 36.74x | -- | $4.24B |
GRDNUSGuardian Pharmacy Services | 37.90x | 56.67% | $2.50B |
ADUSUSAddus Homecare | 21.60x | 18.27% | $2.27B |
VMDUSViemed Healthcare | 25.75x | 11.71% | $373.26M |
INFUUSInfusystem | 32.50x | 37.64% | $277.65M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
